Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02225639 · ClinicalTrials.gov registry record · Phase 3
PRC-063 in an ADULT Workplace Environment
A Phase 3 study of Attention Deficit Hyperactivity Disorder (ADHD), sponsored by Rhodes Pharmaceuticals, L.P..
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT02225639 is a Phase 3 study of Attention Deficit Hyperactivity Disorder (ADHD) that has completed, run by Rhodes Pharmaceuticals, L.P.. The registered enrollment target is 60 participants, below the 144-participant average among 15 other Attention Deficit Hyperactivity Disorder (ADHD) trials with a reported enrollment target (58% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02225639, a Phase 3 study of Attention Deficit Hyperactivity Disorder (ADHD), has completed, sponsored by Rhodes Pharmaceuticals, L.P..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of this study is to assess the time of onset and time course of efficacy over 16 hours of PRC-063 compared to placebo in adults diagnosed with ADHD in a simulated adult workplace environment (AWE) setting, as measured by the PERMP (an individually-adjusted math test) at pre-dose, 1.0, 2.0, 5.0, 8.0, 11.0, 14.0 and 16.0 hours post-dose.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PRC-063 25 mg
- DRUG PRC-063 45 mg
- DRUG PRC-063 35 mg
- DRUG PRC-063 55 mg
Study Locations (2)
California
- AVIDA, Inc. - Newport Beach
Nevada
- Center for Psychiatry and Behavioral Medicine Inc. - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02225639
The ClinicalTrials.gov registry entry for NCT02225639 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 144-participant average among 15 other Attention Deficit Hyperactivity Disorder (ADHD) trials with a reported enrollment target (58% lower). The listed sponsor is Rhodes Pharmaceuticals, L.P., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder (ADHD) appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT02225639 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Nevada.
Frequently Asked Questions
What is clinical trial NCT02225639 about?
NCT02225639 is a clinical study titled "PRC-063 in an ADULT Workplace Environment". The primary objective of this study is to assess the time of onset and time course of efficacy over 16 hours of PRC-063 compared to placebo in adults diagnosed with ADHD in a simulated adult workplace environment (AWE) setting, as measured by the PERMP (an individually-adjusted math test) at pre-dos...
What is the current status of trial NCT02225639?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2014-08. Estimated completion is 2015-05.
What conditions does trial NCT02225639 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder (ADHD).
What interventions are being tested in trial NCT02225639?
The interventions under investigation include: Placebo (DRUG), PRC-063 25 mg (DRUG), PRC-063 45 mg (DRUG), PRC-063 35 mg (DRUG), PRC-063 55 mg (DRUG).
Who is sponsoring clinical trial NCT02225639?
This trial is sponsored by Rhodes Pharmaceuticals, L.P., which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02225639 being conducted?
This trial has 2 study locations across California, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder (ADHD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
COMPLETED · Phase 3
-
Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
COMPLETED · Phase 3
-
Improving ADHD Teen Driving - Virtual Reality
RECRUITING · NA
-
Examination of the Dynamic Relationships of Sleep, Physical Activity, and Circadian Rhythmicity With Neurobehavioral Heterogeneity in ADHD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.